Advertisement


A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer

2016 ASCO Annual Meeting

Advertisement

A. Oliver Sartor, MD, of Tulane University, and Celestia S. Higano, MD, of the University of Washington, discuss findings from this phase III study on cabazitaxel vs docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (Abstract 5006).



Related Videos

Global Cancer Care

Nagi S. El-Saghir, MD, PhD, and Mary Gospodarowicz, MD, on The Middle Eastern Perspective of Cancer Research

Nagi S. El-Saghir, MD, of the American University of Beirut, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international point of view.

Breast Cancer

Nikhil Wagle, MD, on The Metastatic Breast Cancer Project: Progress Report

Nikhil Wagle, MD, of the Dana-Farber Cancer Institute, discusses the strides made in this national direct-to-patient initiative to accelerate genomics research (Abstract LBA1519).

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this interview, please click here.

Skin Cancer

Anthony J. Olszanski, RPh, MD, and Michael A. Davies, MD, PhD, on the COMBI-d Study on Cutaneous Melanoma

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Davies, MD, PhD, of the University of Texas MD Anderson Cancer Center, discuss this phase III study of dabrafenib plus trametinib vs dabrafenib monotherapy in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma (Abstract 9502).

Gastrointestinal Cancer
Gastroesophageal Cancer

Salah-Eddin Al-Batran, MD, on Gastric and GEJ Adenocarcinoma: Results From the FAST Trial

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses findings from this international phase II study of epirubicin, oxaliplatin, and capecitabine with or without IMAB362, as first-line treatment of gastric and gastroesophageal junction adenocarcinoma (Abstract LBA4001).

Advertisement

Advertisement




Advertisement